News Keytruda Approved as First-Line Treatment for Persistent, Recurrent or Metastatic Cervical Cancer Publish Date October 13, 2021 The approval was based on data from the phase 3 KEYNOTE-826 trial.
Drugs in the Pipeline Tisotumab Vedotin Under Review for Recurrent or Metastatic Cervical Cancer Publish Date April 13, 2021 Tisotumab vedotin is an investigational antibody-drug conjugate targeted to tissue factor.